Euclidean Capital LLC Ngm Biopharmaceuticals Inc Transaction History

Euclidean Capital LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.05 - $3.37 $257,768 - $827,314	245,494 Added 32.88%	992,168 $1.06 Million
Q4 2021 Feb 14, 2022	SELL	$17.26 - $22.02 $1.48 Million - $1.88 Million	-85,600 Reduced 10.29%	746,674 $13.2 Million
Q3 2021 Nov 15, 2021	SELL	$20.15 - $26.19 $13.3 Million - $17.3 Million	-661,075 Reduced 44.27%	832,274 $17.5 Million
Q1 2021 May 17, 2021	SELL	$24.99 - $31.93 $14.8 Million - $18.8 Million	-590,253 Reduced 28.33%	1,493,349 $43.4 Million
Q4 2020 Feb 12, 2021	BUY	$16.21 - $31.44 $33.8 Million - $65.5 Million	2,083,602 New	2,083,602 $63.1 Million

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Euclidean Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Euclidean Capital LLC with notifications on news.